Shining light on vitamin D trials in chronic kidney disease.
Vitamin D compounds may have extraskeletal functions. Chronic kidney disease (CKD) offers an opportunity to investigate these actions, as vitamin D deficiency is prevalent in this population and actions of vitamin D such as those on the heart and glucose metabolism are highly relevant. However, recent randomized controlled trials have tempered enthusiasm. We appraise a trial by de Boer et al. that addresses effects of paricalcitol on glucose metabolism in CKD, and offer perspectives on future trials.
Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Sagar U
SU
Nigwekar
Ravi I
RI
Thadhani
D004872:Ergocalciferols / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000378:metabolism
D004872:Ergocalciferols; C084656:paricalcitol; D005947:Glucose